Biosimilars and biologic Drugs

Biosimilars are the generic version of biological. A biosimilar is a biologic therapeutic item which is duplicate of a unique item that is produced by an alternate organization. It is the new buzz word in pharmaceutical industry. Biosimilars are highly comparable to licensed reference product not accept minor differences in clinically passive components; also there are no clinically needful disparities between the biologicals and the reference product in terms of safety, purity, and potency.Biologic Drugs are genetically occurred from a living organism, such as a virus, protein, to maintain the body’s natural response to infections and diseases. Biologics target proteins, and cells responsible for the manifestation and damage of rheumatoid arthritis and other types of inflammatory arthritis. The proteins targeted include tumors necrosis factor (TNF), interleukin-1 (IL-1) and interleukin-6 (IL-6), which shows effect in joint inflammation. Biologics are reserved for people whose arthritis has not retorted well to disease-modifying anti rheumatic drugs (DMARDs).

 

  • Analytical Strategies for Biosimilars
  • Clinical development of biosimilars
  • Globalization of Biosimilars
  • Biosimilar GMP protein analysis
  • Advances in biological products
  • Generic biological drugs

Related Conference of Biosimilars and biologic Drugs

Biosimilars and biologic Drugs Conference Speakers